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Summary
Background: Rotavirus gastroenteritis is a significant cause of morbidity and mortality.
Objective: To perform an integrated safety analysis of data from the Phase III studies of the
pentavalent rotavirus vaccine (PRV).
Methods: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week
intervals in 3 Phase III, blinded, randomized, placebo-controlled trials. Active surveillance for
serious adverse events (AE), including intussusception, was performed at 7, 14, and 42 days
after each dose. Other AEs occurring within 42 days after each dose were documented on
Vaccination Report Cards. Fecal shedding of vaccine-virus strains was evaluated by plaque assay
and electropherotyping.
Results: Intussusception and other serious AEs were evaluated among 71 799 vaccinated sub-
jects. Within 42 days after any dose, intussusception occurred among 6 PRV and 5 placebo
recipients. All AEs were evaluated among 11722 vaccinated subjects. Within the week following
the first dose, the incidences of fever and irritability were similar among PRV and placebo
recipients, although diarrhea and vomiting occurred more frequently among PRV recipients
versus placebo recipients (10.4% vs. 9.1% and 6.7% vs. 5.4%, respectively). Fecal shedding of
vaccine-virus strains occurred in 8.9% of 360 PRV recipients after the first dose.
Conclusions: Across the 3 Phase III clinical trials, PRV was well tolerated, with no increased
clinical risk of intussusception. Fecal shedding of vaccine-virus strains occurred infrequently
and in low amounts, suggesting the risk of transmission is unlikely.
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Introduction
Rotavirus gastroenteritis has been shown to be preventable
with the use of live oral rotavirus vaccines. In 1998,
the only approved rotavirus vaccine, a tetravalent rhesus-
based rotavirus vaccine (RRV-TV, RotaShield™, Wyeth Labo-
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ratories, Philadelphia, Pennsylvania, USA), was withdrawn
from the market in the United States because of an as-
sociation with an increased risk of intussusception among
vaccinated infants.1 At the time of the withdrawal of RRV-
TV, a pentavalent rotavirus vaccine (PRV; RotaTeq™, Merck
& Co., Inc., Whitehouse Station, New Jersey, USA) was in
clinical development, being evaluated in a dose-ranging
Phase II study.2
Despite the withdrawal of RRV-TV, the clinical devel-
opment of PRV continued because: (1) the public health
burden of rotavirus gastroenteritis was significant; (2) nat-
ural rotavirus infection was not thought to be a significant
contributing factor to intussusception; (3) PRV and RRV-TV
had significant preclinical and clinical differences3; and (4)
the clinical safety and efficacy profile of PRV up to that
point had been favorable.
Because the etiology of intussusception following RRV-
TV remained unclear, however, a large-scale clinical trial
was required to evaluate the safety of PRV with respect
to intussusception. The Rotavirus Efficacy and Safety Trial
(REST) was a large-scale Phase III study among nearly
70 000 subjects designed specifically to address the risk
of intussusception with PRV.3 Furthermore, a subset of
subjects in REST were studied in detail to assess other
potential adverse experiences (e.g., fever, diarrhea, and
vomiting). Additional detailed safety data were collected
in 2 other Phase III trials --- Study 007, a study among
1310 vaccinated subjects4 evaluating the efficacy of PRV at
the end of expiry potency (end of the 24-month shelf-life
of the vaccine) and Study 009, a study among 793 vacci-
nated subjects evaluating the clinical consistency of the
manufacturing process of PRV. Thus, combining data from
Studies 007 and 009 adds more than 2000 subjects with
detailed safety information to the REST detailed safety
cohort. This article is the first report of safety information
across the Phase III clinical program for PRV.
Methods
In REST, Study 007, and Study 009, healthy 6- to 12-
week-old infants were randomized to receive 3 doses of
PRV, which is composed of 5 human-bovine reassortant
rotaviruses of the WC3 (bovine G6) strain, including 4 VP7
reassortants (human rotavirus G1, G2, G3, and G4) and
1 VP4 reassortant (human P1A[8]), or placebo at 4- to
10-week intervals.
Intussusception and serious adverse events among
the large-scale cohort
Active surveillance for serious adverse events (SAEs), in-
cluding intussusception, was performed at 7, 14, and 42
days after each dose of PRV or placebo in all Phase III stud-
ies. In REST, subjects also were contacted every 6 weeks
for 1 year after the first dose. In Study 007, 2 cohorts
were enrolled and data on potential intussusception cases
were collected through the end of 2 rotavirus seasons, 1
cohort per season. All Phase III studies collected data on
vaccine-related SAEs and deaths throughout the study.
Detailed safety cohort
For a subset of subjects within REST and all subjects
from Studies 007 and 009, parents/guardians were asked
to report all AEs on the Vaccination Report Card for 42
days after each dose. They were also asked to record
temperature and any episodes of diarrhea and vomiting on
a daily basis during the first week following each dose.
Fecal shedding of vaccine-virus strains evaluated by
plaque assay
Fecal shedding of vaccine-virus strains was evaluated in
REST and Study 007. In REST, a prospectively defined sub-
set of approximately 300 subjects was evaluated for fecal
shedding of vaccine-virus strains 4 to 6 days after each
dose. In addition, fecal samples from all subjects from
both REST and Study 007 with potential acute gastroen-
teritis episodes that were positive by the rotavirus enzyme
immunoassay were evaluated. Vaccine-virus strains were
identified using viral culture with plaque assay and RNA
electropherotyping.5
Statistical analysis
All subjects who received at least 1 dose and who had
follow-up evaluations were included in the safety analysis.
For the evaluation of intussusception in REST, the primary
hypothesis was that vaccine, relative to placebo, would
not increase the risk of intussusception within 42 days
after any dose. To satisfy this hypothesis, 2 prespecified
criteria had to be met. During the study, there could not
be a significantly increased risk of intussusception among
vaccine recipients relative to placebo recipients within 7
days and 42 days after any dose (i.e., the lower bound
of the 95% confidence interval [CI] could not be >1.0). In
addition, at the end of the study, the upper bound on the
95% CI for the relative risk of intussusception within 42
days after any dose had to be 10 or less.
Two independent committees were involved with all
Phase III studies. First, an independent committee blinded
to treatment arm, which included a pediatric surgeon,
a pediatric radiologist, and a pediatrician with extensive
experience in emergency medicine, adjudicated potential
intussusception cases using a prespecified case definition.
Second, as each positively-adjudicated case of intussus-
ception was reported, an independent data and safety
monitoring board (DSMB) unblinded the treatment arm of
the case and reviewed the ratio of cases in the vaccine
versus placebo recipients. If, at any time during the 7- or
42-day period after any dose, the risk of intussusception
was significantly higher in the vaccine group than in the
placebo group, the DSMB was to recommend halting all on-
going studies. For REST, the DSMB also determined whether
the end-of-study criteria had been met by evaluating the
risk of intussusception after 60 000 infants had been en-
rolled. If the criteria had not been met, additional groups
of 10 000 subjects, up to a maximum of 100 000, could
be enrolled and the monitoring described above would
continue.
The primary hypothesis for REST was tested with the use
of an exact binomial procedure based on the proportion of
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subjects with intussusception who received vaccine. The
study was designed to have a 94% probability of accept-
ing the primary hypothesis if the vaccine was safe (i.e.,
relative risk = 1).
The frequency of other SAEs was summarized across
the 3 studies. The frequency of AEs of specific interest
(i.e., diarrhea, fever [temperature ≥38.1°C, rectal equiv-
alent], irritability, and vomiting) within the first week
after a dose was compared between treatment groups with
risk differences and p-values, based on exact binomial
procedures.
Results
Subjects
Table 1 describes the disposition of subjects enrolled in
the Phase III clinical development program for PRV. Of the
subjects enrolled in the studies, 33 115 in the PRV group
(91.3%) and 32 531 in the placebo group (91.2%) completed
the 3-dose series and 42 days of follow-up. A total of 81 of
36 271 randomized subjects (0.2%) in the PRV group and 97
of 35 671 randomized subjects (0.3%) in the placebo group
were lost to follow-up. Other reasons for not completing
the study included clinical AEs, protocol deviations, refusal
to participate further, and moving to another area. Table 2
describes the demographic characteristics of the subjects
in the Phase III studies. The characteristics of infants in the
PRV group were comparable to the characteristics of the
placebo group.
Intussusception and serious adverse events
The risk of intussusception and other SAEs was evaluated
among 71 799 subjects vaccinated with at least 1 dose of
PRV or placebo in the Phase III program. In REST, overall,
28 intussusception cases were reported within the 1-year
observation period, 13 among PRV and 15 among placebo
recipients (RR = 0.9; 95% CI: 0.4, 1.9). Eleven of those
cases of intussusception were reported during the primary
timeframe of interest (the three 42-day postdose periods),
6 among PRV and 5 among placebo recipients. The asso-
ciated relative risk was 1.2 with a 95% CI of 0.3 to 5.0.
Because it was necessary to enroll an additional 10 000
subjects beyond the initial 60 000 subjects, the relative
Table 1 Disposition of subjects
PRV Placebo
Number randomized, n 36 271 35671
Completed dose 3 + 42-day safety follow-up period, n (%) 33 115 (91.3) 32 531 (91.2)
Discontinued, n (%) 3 156 (8.7) 3 140 (8.8)
Clinical adverse event 235 (0.6) 220 (0.6)
Protocol deviation 1 106 (3.0) 1 160 (3.3)
Refused further participation 232 (0.6) 237 (0.7)
Lost to follow-up 81 (0.2) 97 (0.3)
Moved 228 (0.6) 220 (0.6)
Other 1 274 (3.5) 1 206 (3.4)
PRV = pentavalent rotavirus vaccine.
Table 2 Demographic characteristics of subjects
enrolled in the Phase III Clinical Development Program of
the pentavalent rotavirus vaccine
Characteristic PRV Placebo
Subjects randomized, n 36 271 35 671
Gender, n (%)
Male 18 441 (50.8) 18 083 (50.7)
Age at entry, wk
Mean (SD) 9.8 (1.4) 9.8 (1.4)
Race, n (%)
White 24 969 (68.8) 24 624 (69.0)
Hispanic 5 214 (14.4) 5 025 (14.1)
Black 2 990 (8.2) 2 985 (8.4)
Other 3 098 (8.6) 3 037 (8.5)
PRV = pentavalent rotavirus vaccine.
Figure 1 Age of infants at diagnosis of intussusception from the
Rotavirus Efficacy and Safety Trial (adapted with permission from
Vesikari et al., 20063).
risk calculations were adjusted for multiplicity, resulting
in a relative risk of 1.6 with a 95% CI of 0.4 to 6.4.
None of the intussusception cases occurred among PRV
recipients within the 42-day period after the first dose.
Among PRV recipients, there was no clustering of cases in
time. The incidence of intussusception among infants in
REST was 1 in 2253 infants overall and 1 in 2101 among
placebo recipients. Figure 1 displays for REST the age
of infants at diagnosis of intussusception. No confirmed
cases of intussusception were reported in Studies 007 and
009.
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Table 3 Summary of serious adverse events occurring
within 42 days after any dose during the Phase III studies
among the large-scale study cohort
Event Number (%) of subjects
PRV Placebo
n = 36150 n = 35 536
No SAEs 35 289 (97.6) 34 614 (97.4)
SAEs 861 (2.4) 922 (2.6)
Bronchiolitis 226 (0.6) 257 (0.7)
Gastroenteritis 73 (0.2) 117 (0.3)
Dose-related SAEs 49 (0.1) 79 (0.2)
Gastroenteritis 17 (<0.1) 33 (0.1)
Fever 8 (<0.1) 12 (<0.1)
Dehydration 3 (<0.1) 13 (<0.1)
Deaths 15 (<0.1) 13 (<0.1)
Discontinued due to an SAE 83 (0.2) 72 (0.2)
PRV = pentavalent rotavirus vaccine; SAE = serious adverse
event.
n = number of subjects with follow-up.
Table 3 summarizes the SAEs reported during the Phase
III studies among the large-scale study cohort. During the
42-day period after any dose, 2.4% of PRV recipients and
2.6% of placebo recipients reported SAEs. The most com-
monly reported SAEs were bronchiolitis and gastroenteritis,
which occurred with comparable frequency among PRV and
placebo recipients. Gastroenteritis, fever, and dehydration
were the most frequently reported SAEs related to PRV
or placebo as assessed by investigators who were blinded
to treatment arm. The frequency of these SAEs in infants
receiving PRV was comparable to their frequency in infants
receiving placebo. Discontinuations due to an SAE occurred
in 0.2% of each treatment group. Overall, 52 deaths oc-
curred during the Phase III studies (25 in the PRV group
and 27 in the placebo group). Within the 42-day period
after any dose, 15 deaths occurred among PRV recipients
and 13 deaths occurred among placebo recipients. The
most common cause of death was sudden infant death syn-
drome. Cases of sudden infant death syndrome were evenly
distributed between treatment groups (8 deaths among the
PRV group and 9 deaths among the placebo group). No
deaths were attributed to vaccination by investigators
blinded to treatment assignment.
Detailed safety results
The detailed safety cohort was comprised of a subset of ap-
proximately 9600 subjects in REST and approximately 2100
subjects from Studies 007 and 009. Among the subjects
(6143 PRV and 5579 placebo recipients) in the pooled anal-
ysis of detailed safety, the rates of vomiting and diarrhea
within the week after the first dose were increased among
vaccine recipients (P < 0.05) (Figure 2a). The difference
between the PRV and placebo groups for each of these
events was 1.3%. The majority of episodes of diarrhea
and vomiting were reported as mild. Irritability occurred
in 7.1% of both treatment groups. As shown in Figure 2b,
Figure 2 (a) Percentages of infants from the Detailed Safety
Cohort with vomiting, diarrhea, and irritability within 1 week after
the first dose by vaccination group. a P-value (2-sided) < 0.05.
(b) Percentages of infants from the Detailed Safety Cohort with
fever within 1 week after any dose by vaccination group and dose
number. Fever = temperatures ≥38.1°C, rectal equivalent.
the rate of fever (temperature ≥38.1°C, rectal equivalent)
within the first week after each dose among infants in the
detailed safety cohort was comparable between PRV and
placebo recipients.
Fecal shedding of vaccine-virus strains as evaluated
by plaque assay
Results from the pooled analysis of data from REST and
Study 007 showed that the incidence of shedding of
vaccine-virus strains was low and occurred primarily after
the first dose (Table 4). In the PRV group, 32 of 360 infants
(8.9%) shed vaccine-virus strains after the first dose. After
the second dose, none of the infants shed vaccine-virus
strains, and after the third dose, 1 infant in the PRV group
Table 4 Fecal shedding of vaccine-virus strains among
vaccine recipients occurring any time in REST and Study
007
Dose number Number of shedders/number tested
(%)
One 32/360 (8.9)
Two 0/249 (0)
Three 1/385 (0.3)
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(4 days after the dose) shed vaccine-virus strains. Shedding
was observed as early as Day 1. One infant shed at Day 15
after the first dose, which was the latest point in which
shedding was observed. Shedding peaked at Day 4–6. The
quantity of virus shed was approximately 5 × 101 to 1.9 ×
104 PFU/mL (average: 1.8 × 103).
Discussion
The REST study provides a high level of confidence in the
safety of PRV with respect to intussusception. The overall
rate of intussusception in REST (1 in 2253 or 0.04%) was
consistent with the expected background rate of intussus-
ception. Rennels and colleagues6 evaluated the background
rates of intussusception by obtaining data from 269 832
children younger than 5 years of age hospitalized during
the period from 1991 through 1995 with an International
Classification of Disease (ICD) 9-CM code for rotavirus
diarrhea (008.61) or intussusception (560) from the New
York Statewide Planning and Research Cooperative System.
The rate of intussusception among these children was 136
of 269 832 annually (0.05%). The age at diagnosis of intus-
susception in REST also appears to mirror the background
Figure 3 Age of infants at diagnosis of intussusception from the
New York Statewide Planning and Research Cooperative System,
1991---95 (reproduced with permission from Rennels et al., 19986).
Figure 4 Cases of intussusception associated with the tetravalent rhesus rotavirus vaccine (RRV-TV) by dose (reproduced with permission
from Murphy et al., 20017).
rate of intussusception. Figure 3 depicts the age of sub-
jects hospitalized with intussusception from the New York
Statewide Planning and Research Cooperative System.6 The
peak age of intussusception for both REST and the New
York State data was 5 months.
Importantly, the profile of intussusception cases ap-
peared to differ from that observed during postlicensure
studies with RRV-TV in that there was no clustering of
cases in time and no shift of cases to younger infants, in
whom background cases would not be expected. A case-
control analysis of intussusception cases following RRV-TV
determined that cases of intussusception generally were
clustered in the 3- to 14-day period following Dose 1 and
the 3- to 7-day period following Dose 2 (Figure 4).7 In REST,
cases of intussusception were not clustered in time and
there were no cases reported among vaccine recipients
within the 42 days following Dose 1. Because the pattern of
intussusception cases following RRV-TV was clustered after
the first dose and cases were shifted to a younger age
than expected, the REST study was designed to ensure that
any risk of intussusception attributable to vaccine would
have been identified as early as possible. At 6 to 12 weeks
(42 to 84 days) of age, when the first dose was received,
background intussusception is very rare. Therefore, it
would be easier to differentiate vaccine-related cases from
background cases should they occur. If the risk of intussus-
ception with PRV had been similar to that of RRV-TV, the
probability of stopping REST early because of detecting a
statistically significant increase in intussusception risk dur-
ing the study would have been 85% to 91%. Therefore, it is
highly likely that the design of REST would have identified
the association between RRV-TV and intussusception. In
contrast, REST found no increased clinical risk of intussus-
ception with PRV relative to placebo. Overall, the profile
of intussusception cases in REST was comparable to that of
background intussusception cases with respect to overall
incidence, age of cases, and sporadic occurrence (i.e., lack
of clustering during biologically relevant timeframes).
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PRV is a live virus vaccine. A potential concern with any
live vaccine is that it may cause the very symptoms it is de-
signed to prevent. The clinically important symptoms eval-
uated for this vaccine are vomiting, diarrhea, and fever,
particularly during the first week after a dose, during the
peak of vaccine-virus replication. There were no significant
increases in fever (temperature ≥38.1°C, rectal equiva-
lent) or irritability following the first dose of PRV when
data from the Phase III studies were combined. However,
there were small increases (1.3% difference between PRV
and placebo) in the incidence of diarrhea and vomiting af-
ter the first dose of PRV. Although the REST detailed safety
subset included 9619 subjects, it is interesting to note
that these differences were only statistically significant
when the results from the additional 2103 subjects from
Studies 007 and 009 were combined with those of REST.
When these outcomes were evaluated in the individual
studies, there were no statistically significant differences
except for the fever outcome in Study 007. In Study 007,
a statistical increase in fever was found among vaccine
recipients (13.4%) compared with placebo recipients (8.8%)
after Dose 1, although there was no increase after Dose
2 or Dose 3.4 Because this is a live vaccine, these slight
increases are not unexpected. The observed frequencies of
these events were less than the clinically and statistically
significant frequencies of similar events that occurred
during the first 5 days following the first dose of RRV-TV.9
Results from the pooled analysis of data from the Phase
III trials showed that, overall, the incidence of shedding of
vaccine-virus strains with PRV was low; shedding primarily
occurred after the first dose, and the quantity of virus shed
was relatively low (i.e., approximately 0.001% to 1% of the
PRV dose). Because this is a live virus vaccine, there is the
potential for shedding of vaccine-virus in the feces. Shed-
ding may be perceived as either beneficial or detrimental.
A potential benefit of shedding of vaccine-virus stains is
transmission to unvaccinated persons and the potential for
contact immunity, albeit this benefit may be more highly
regarded in developing countries where vaccine coverage
is relatively low compared with industrialized countries.
A potentially unfavorable outcome would be transmission
to an immunocompromised individual. Because nearly all
children are infected with rotavirus by the age of 5 years,8
most immunocompromised contacts of young infants and
children have a high probability of exposure to wild-type
rotavirus. One may consider exposure to an attenuated
vaccine-virus, such as the bovine strain included in PRV,
preferable to contracting natural infection, in which ro-
tavirus shedding occurs at a rate of approximately 1010- 12
per gram of feces10. Because shedding of vaccine-virus
strains with PRV is low and in small quantities, the risk of
transmission is unlikely. In addition, ACIP endorses the use
of PRV for HIV-exposed/infected infants based on 3 main
considerations: 1) the HIV diagnosis may not be established
before the age of the first dose, 2) natural rotavirus in-
fection does not appear to be more severe in HIV-infected
infants; and 3) PRV is considerably attenuated.11 However,
studies to specifically evaluate transmission and evalua-
tion in developing countries, where the disease burden is
greater, have not been conducted.
It is important to note that despite the large sample
size, fewer than 1% of subjects in the study were lost
to follow-up, emphasizing the high quality the data and
rigorousness of follow-up of subjects in the study. Overall,
these studies demonstrated a favorable safety profile for
PRV; however, in light of the history of intussusception
associated with RRV-TV, extensive postmarketing surveil-
lance plans are being carried out to continue to monitor
the safety of PRV and thoroughly investigate any poten-
tial safety signals. In response to requests by regulatory
authorities in this regard, the manufacturer of PRV is con-
ducting enhanced passive reporting and active surveillance
targeting intussusception and general safety in a large
population of vaccinated infants. These measures extend
beyond the routine safety reporting systems generally fol-
lowed postlicensure and are designed to coordinate with
and complement the existing systems provided through the
Food and Drug Administration (i.e., Vaccine Adverse Event
Reporting System) and Centers for Disease Control and
Prevention (i.e., Vaccine Safety Datalink), and surveillance
efforts in the European Union. Using these postlicensure
monitoring systems, as of mid-June 2007, no safety signal
has been identified and this includes the combined safety
data of approximately 105 000 doses for the clinical trials;
70 000 doses for the Vaccine Safety Datalink; 7000 doses in
the Merck postlicensure study; and 16 months of Vaccine
Adverse Events Reporting System data, which involved
approximately 6.2 million doses distributed in the United
States. Monitoring will continue.11
Conclusions
In summary, these data, including studies with large sample
sizes and rigorous follow-up, demonstrate that PRV was
well tolerated with respect to intussusception and other
AEs. Given the excellent efficacy of PRV, described in
the article by Vesikari also in this supplement, and the
public health burden of rotavirus disease, this vaccine is
an important public health tool to reduce the morbidity
and mortality of rotavirus disease in infants and young
children.
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